The Treatment of Newly Diagnosed CD19+Mixed Phenotype Acute Leukemia in Adults

Inclusion criteria

• Patients fully understand this study, voluntarily participate and sign an informed consent form (ICF);
• Age: 18-75 years old (including boundary values of 18 and 75);
• Clinically diagnosed adult Mixed Phenotype Acute Leukemia (WHO 2016 criteria) patients with CD19 positivity

Exclusion criteria

The subject's previous history of anti-tumor treatment meets one of the following conditions:

• Individuals who have previously received bevacizumab
• Individuals who have received CAR-T therapy or other gene modified cell therapies prior to screening;
• Within 5 half lives of the first use of the investigational drug, having received anti-tumor treatment including surgery, chemotherapy, targeted therapy, or participating in other clinical trials and receiving clinical trial medication;